Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 214 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: BPH Clear all
Completed Not applicable Interventional Results available

The Value of Multiple Urine Flow Rate Measurements in Male Benign Prostatic Hyperplasia (BPH) Subjects

NCT00710749
View directory record Official record
Conditions
Bladder Outlet Obstruction, Lower Urinary Tract Symptoms
Interventions
Disposable device, Digital device, Clinic flow measurement
Device
Lead sponsor
Wellspect HealthCare
Industry
Eligibility
45 Years to 85 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)

NCT02026908
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 20, 2026, 7:24 PM EDT
Terminated No phase listed Observational

Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode

NCT02019030
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Loma Linda, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 20, 2026, 7:24 PM EDT
Recruiting No phase listed Observational

Customized TULSA-PRO Ablation Registry

NCT05001477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Interventions
TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2061
U.S. locations
5
States / cities
West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres

NCT03052049
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Prostate Artery Embolization
Device
Lead sponsor
Northwestern University
Other
Eligibility
45 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

NCT00547625
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostate
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

NCT01939184
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
WC3055, Placebo
Drug · Other
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years and older · Male only
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
95
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States

NCT02184585
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
Treatment sequence A, Treatment sequence B, Treatment sequence C
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 20, 2026, 7:24 PM EDT
Terminated No phase listed Observational

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

NCT03768765
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Holmium Laser Prostate Surgery
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial

NCT04263987
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Moses laser enucleation of prostate
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

NCT01107392
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
botulinum toxin Type A, Normal saline
Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 20, 2026, 7:24 PM EDT
Completed No phase listed Observational Results available

An Observational Study of Radial Access Embolization Procedures Using HydroPearl Microspheres

NCT04272216
View directory record Official record
Conditions
Uterine Fibroid, Arteriovenous Malformations, Hypervascular Tumors, Benign Prostatic Hyperplasia
Interventions
Treatment with HydroPearl via radial access
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 20, 2026, 7:24 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo

NCT00224120
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Silodosin, Placebo
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Birmingham, Alabama • Carmichael, California • Fresno, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 20, 2026, 7:24 PM EDT
Completed No phase listed Observational

Identification and Treatment of Men With BPH in the Primary Care Setting

NCT00211640
View directory record Official record
Conditions
No Conditions for This Study. All Male Patients 18 Years of Age or Older Were Administered the LUTS, MSHQ, and Patient Demographics Questionnaire
Interventions
Not listed
Lead sponsor
Mid Michigan Health Centers
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Jackson, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Oct 20, 2026, 7:24 PM EDT
Terminated Phase 2 Interventional Results available

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

NCT03297398
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo
Drug · Other
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Anniston, Alabama • Lincoln, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 20, 2026, 7:24 PM EDT
Not yet recruiting No phase listed Observational

The FLOW Registry.

NCT07430423
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 7:24 PM EDT
Withdrawn Phase 4 Interventional

Role of Prophylactic Postoperative Antibiotics in HoLEP

NCT05274672
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Urinary Tract Infections
Interventions
Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination, Ciprofloxacin, Holmium Laser Enucleation of prostate
Drug · Procedure
Lead sponsor
Baylor Research Institute
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 7:24 PM EDT
Not yet recruiting Not applicable Interventional

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

NCT07772232
View directory record Official record
Conditions
Benign Prostate Hypertrophy(BPH), Lower Urinary Track Symptoms
Interventions
Device - HoLEP with MOSES 2.0, RWJA with Hydros Robotic System
Device
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 7:24 PM EDT
Not listed Not applicable Interventional

Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia

NCT02592473
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign Prostatic Hyperplasia (BPH), Prostatism, Lower Urinary Tract Symptoms (LUTS), Prostatic Hypertrophy, Hyperplasia, Male Urogenital Diseases, Genital Diseases, Male
Interventions
Embozene Microspheres
Device
Lead sponsor
University of Virginia
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 20, 2026, 7:24 PM EDT
Completed No phase listed Observational Results available

GreenLight XPS Laser System Retrospective Chart Review

NCT02139969
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
GreenLight XPS Laser System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Male only
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Mountain View, California • Atlanta, Georgia • Westland, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 20, 2026, 7:24 PM EDT
Recruiting Phase 2 Interventional

Effects of TNF Blockade on Human BPH/LUTS

NCT06062875
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Adalimumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 20, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)

NCT01846793
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, BPH, Lower Urinary Tract Symptoms (LUTS), LUTS
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Laguna Beach, California • San Diego, California • Aventura, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 20, 2026, 7:24 PM EDT